12/12/2025
CureLeads is proud to have participated in a key strategic meeting with the Egyptian Drug Authority (EDA), headed by Dr. Ali Al-Ghamrawy, to discuss ways to enhance access to innovative, high-quality pharmaceutical therapies in the Egyptian market.
During the discussion, CureLeads team presented a detailed overview of the scientific and technical aspects of our products, highlighting our commitment to bringing advanced treatments to patients in Egypt.
We also explored opportunities to accelerate regulatory pathways in alignment with the Authority’s vision for ensuring quality, safety, and efficiency without compromise.
We extend our deepest appreciation to the EDA for its continued efforts to support innovation, foster investment, and ensure timely access to modern therapies.
CureLeads attendees:
• Dr. Mohammad Rammal, CEO
• Dr. Bahr Joujou, Head of BD
DAF attendees:
• Eng. Hatem Qandil, CEO
• Dr. Alaa, Head of marketing & Pharma
CureLeads remains committed to working collaboratively with health authorities and DAF partner to ensure that patients benefit from cutting-edge treatments that meet the highest international standards.
Together, we move forward with a shared purpose:
Empowering patients with faster, safer access to the latest global innovations in healthcare.
